Skip to main content
SpringerLink
Log in

Drug Administration and Pharmacogenomics in Children Receiving Acute or Chronic Renal Replacement Therapy

  • Chapter
  • First Online:
Pediatric Dialysis

  • 1929 Accesses

Abstract

The prescription of a safe and effective dose of a medication for a child receiving dialysis is an arduous task as both renal failure and dialysis can modify the absorption, distribution, metabolism, elimination, and action of a drug. A safe and effective dosing regimen is one that delivers the appropriate drug in the optimal manner, producing the desired pharmacological response while minimizing the undesirable effects. Achieving the goal of successful drug therapy requires a clear understanding of the therapeutic goal ­coupled with an appreciation of the factors governing drug disposition and action. Failure to clearly identify the therapeutic goal or to account for the changes in drug disposition associated with renal failure and the performance of dialysis can culminate in drug toxicity or inadequate treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Ritschel W, Kearns GL. Handbook of basic pharmacokinetics…Including clinical applications. 7th ed. Washington, DC: American Pharmaceutical Association; 2009.

    Google Scholar 

  2. Miyagawa CI. Hydrochloric acid given with ketoconazole through a jejunostomy tube. Clin Pharm. 1984;3:205–7.

    PubMed  CAS  Google Scholar 

  3. Blum RA, D’Andrea DT, Florentino BM, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Goldstein H, Schentag JJ. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114:755–7.

    PubMed  CAS  Google Scholar 

  4. Bruni J, Wang LH, Marbury TC, Lee CS, Wilder BJ. Protein binding of valproic acid in uremic patients. Neurology. 1980;30:557–9.

    PubMed  CAS  Google Scholar 

  5. Bauer TM, Ritz R, Haberthur C, Ha HR, Hunkeler W, Sleight AJ, Scollo-Lavizzari G, Haefeli WE. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet. 1995;346:145–7.

    Article  PubMed  CAS  Google Scholar 

  6. Ball M, McQuay HJ, Moore RA, Allen MC, Fisher A, Sear J. Renal failure and the use of morphine in intensive care. Lancet. 1985;1:784–6.

    Article  PubMed  CAS  Google Scholar 

  7. Szeto HH, Inturrisi CE, Houde R, Saal S, Cheigh J, Reidenberg MM. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med. 1977;86: 738–41.

    PubMed  CAS  Google Scholar 

  8. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther. 2008;118:250–67.

    Article  PubMed  CAS  Google Scholar 

  9. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392:1093–108.

    Article  PubMed  CAS  Google Scholar 

  10. Odugbemi T. An open evaluation study of sulbactam/ampicillin with or witohut probenecid in the treatment of gonococcal infections in Lagos. Drugs. 1988;35:89–91.

    Article  PubMed  Google Scholar 

  11. Prescott L, Balali-Mood M, Critchley J, Johnstone A, Proudfoot A. Diuresis or urinary alkalinisation for salicylate poisoning. Br Med J. 1982;285:1383–6.

    Article  CAS  Google Scholar 

  12. Paulson MF, Welling PG. Calculation of serum digoxin levels in patients with normal and impaired renal function. J Clin Pharmacol. 1976;16:660–5.

    PubMed  CAS  Google Scholar 

  13. Blowey DL, Kearns GL, Lalkin A. Special considerations in the prescribing of medications for the pediatric CAPD/CCPD patient. In: Fine RN, Alexander SR, Warady BA, editors. CAPD/CCPD in Children, chap 15. Boston: Kluwer Academic Publishers; 1998. p. 229–46.

    Chapter  Google Scholar 

  14. Zhang Y, Zhang L, Abraham S, Apparaju S, Wu T-C, Strong S, Xiao S, Atkinson A, Thummel K, Leeder JS, Lee C, Burckart GJ, Lesko L, Huang S-M. Assessment of the impact of renal impairment on systemic exposure of new molecular entities – Evaluation of recent new drug applications. Clin Pharmacol Ther. 2009;85:305–11.

    Article  PubMed  CAS  Google Scholar 

  15. Marx MA, Frye RF, Matzke GR, Golper TA. Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. Am J Kidney Dis. 1998;32:410–4.

    Article  PubMed  CAS  Google Scholar 

  16. Zoer J, Schrander-van der Meer AM, Van Dorp WT. Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes. Pharm World Sci. 1997;19:191–6.

    Article  PubMed  CAS  Google Scholar 

  17. DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis. 1992;20:354–60.

    PubMed  CAS  Google Scholar 

  18. Blowey DL. Extracorpeal methods of drug removal. In: Ritschel W, Kearns GL, editors. Handbook of basic pharmacokinetics, chap 38. 7th ed. Washington, DC: American Pharmaceutical Association; 2009. p. 395–407.

    Google Scholar 

  19. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy. 2000;20:635–43.

    Article  PubMed  CAS  Google Scholar 

  20. Warady BA, Schaefer F, Holloway M, Alexander S, Kandert M, Piraino B, Salusky I, Tranaeus A, Divino J, Honda M, Mujais S, Verrina E. Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis. Perit Dial Int. 2000;20: 610–24.

    PubMed  CAS  Google Scholar 

  21. Schaefer F, Klaus G, Muller-Wiefel DE, Mehls O, The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS). Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. J Am Soc Nephrol. 1999;10:136–45.

    PubMed  CAS  Google Scholar 

  22. Li PK-T, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, Johnson DW, Kuijper EJ, Lye W-C, Salzer W, Schaefer F, Struijk DG. ISPD guidelines/recommendations: peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int. 2010;30:393–423.

    PubMed  Google Scholar 

  23. Boelaert J, Schurgers M, Daneels R, Van Landuyt HW, Weatherley BC. Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis. J Antimicrob Chemother. 1987;20:69–76.

    Article  PubMed  CAS  Google Scholar 

  24. Laskin OL, Longstreth JA, Whelton A, Krasny HC, Keeney RE, Rocco L, Lietman PS. Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med. 1982;73:197–201.

    Article  PubMed  CAS  Google Scholar 

  25. Stathoulopoulou F, Almond MK, Dhillon S, Raftery MJ. Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. Nephron. 1996;74:337–41.

    Article  PubMed  CAS  Google Scholar 

  26. Wagstaff AJ, Faulds D, Goa KL. Aciclovir A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47: 153–205.

    Article  PubMed  CAS  Google Scholar 

  27. Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol. 1982;17:19–23.

    PubMed  CAS  Google Scholar 

  28. Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.. 2002;51:1–31.

    PubMed  Google Scholar 

  29. Olyaei AJ, De Mattos A, Bennett W. Prescribing drugs in renal disease. In: Brenner B, editor. The Kidney, chap 61. Philadelphia: WB Saunders; 2000. p. 2606–53.

    Google Scholar 

  30. Chow-Tung E, Lau AH, Vidyasagar D, John EG. Effect of peritoneal dialysis on serum concentrations of three drugs commonly used in pediatric patients. Dev Pharmacol Ther. 1985;8:85–95.

    PubMed  CAS  Google Scholar 

  31. Lanao JM, Dominguez-Gil A, Tabernero JM, Macias JF. Influence of type of dialyzer on the pharmacokinetics of amikacin. Int J Clin Pharmacol Ther Toxicol. 1983;21:197–202.

    PubMed  CAS  Google Scholar 

  32. Armendariz E, Chelluri L, Ptachcinski R. Pharmacokinetics of amikacin during continuous veno-venous hemofiltration. Crit Care Med. 1990; 18:675–6.

    Article  PubMed  CAS  Google Scholar 

  33. Oe PL, Simonian S, Verhoef J. Pharmacokinetics of the new penicillins. Amoxycillin and flucloxacillin in patients with terminal renal failure undergoing haemodialysis. Chemotherapy. 1973;19:279–88.

    Article  PubMed  CAS  Google Scholar 

  34. Muther RS, Bennett WM. Peritoneal clearance of amphotericin B and 5-fluorocytosine. West J Med. 1980;133:157–60.

    PubMed  CAS  Google Scholar 

  35. Block ER, Bennett JE, Livoti LG, Klein Jr WJ, MacGregor RR, Henderson L. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Ann Intern Med. 1974;80:613–7.

    PubMed  CAS  Google Scholar 

  36. Cotterill S. Antimicrobial prescribing in patients on haemofiltration. J Antimicrob Chemother. 1995;36: 773–80.

    Article  PubMed  CAS  Google Scholar 

  37. Jusko WJ, Lewis GP, Schmitt GW. Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects. Clin Pharmacol Ther. 1973;14:90–9.

    PubMed  CAS  Google Scholar 

  38. Golper TA, Pulliam J, Bennett WM. Removal of therapeutic drugs by continuous arteriovenous hemofiltration. Arch Intern Med. 1985;145:1651–2.

    Article  PubMed  CAS  Google Scholar 

  39. Kent JR, Almond MK, Dhillon S. Azithromycin: an assessment of its pharmacokinetics and therapeutic potential in CAPD. Perit Dial Int. 2001;21:372–7.

    PubMed  CAS  Google Scholar 

  40. Berman SJ, Boughton WH, Sugihara JG, Wong EG, Sato MM, Siemsen AW. Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis. Antimicrob Agents Chemother. 1978;14:281–3.

    PubMed  CAS  Google Scholar 

  41. Gartenberg G, Meyers BR, Hirschmann SZ, Srulevitch E. Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis. J Antimicrob Chemother. 1979;5:465–70.

    Article  PubMed  CAS  Google Scholar 

  42. Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1999;19:65–70.

    PubMed  CAS  Google Scholar 

  43. Cronqvist J, Nilsson-Ehle I, Oqvist B, Norrby SR. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment. Antimicrob Agents Chemother. 1992;36:2676–80.

    PubMed  CAS  Google Scholar 

  44. Wong KM, Chan WK, Chan YH, Li CS. Cefepime-related neurotoxicity in a haemodialysis patient. Nephrol Dial Transplant. 1999;14:2265–6.

    Article  PubMed  CAS  Google Scholar 

  45. Barbhaiya RH, Knupp CA, Pfeffer M, Zaccardelli D, Dukes GM, Mattern W, Pittman KA, Hak LJ. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 1992;36:1387–91.

    PubMed  CAS  Google Scholar 

  46. Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J. 1987;6:963–70.

    Article  PubMed  CAS  Google Scholar 

  47. Guay DR, Meatherall RC, Harding GK, Brown GR. Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother. 1986;30: 485–90.

    PubMed  CAS  Google Scholar 

  48. Albin HC, Demotes-Mainard FM, Bouchet JL, Vincon GA, Martin-Dupont C. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1985;38:285–9.

    Article  PubMed  CAS  Google Scholar 

  49. Fillastre JP, Leroy A, Humbert G, Godin M. Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function. J Antimicrob Chemother. 1980;6(Supply A):103–11.

    PubMed  CAS  Google Scholar 

  50. Hoffler D, Koeppe P, Corcilius M, Przyklinik A. Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis. Infection. 1990;18:157–62.

    Article  PubMed  CAS  Google Scholar 

  51. Borin MT, Hughes GS, Kelloway JS, Shapiro BE, Halstenson CE. Disposition of cefpodoxime proxetil in hemodialysis patients. J Clin Pharmacol. 1992;32: 1038–44.

    PubMed  CAS  Google Scholar 

  52. Johnson CA, Ateshkadi A, Zimmerman SW, Hughes GS, Craig WA, Carey PM, Borin MT. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 1993;37:2650–5.

    PubMed  CAS  Google Scholar 

  53. Shyu WC, Pittman KA, Wilber RB, Matzke GR, Barbhaiya RH. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment. J Clin Pharmacol. 1991;31:362–71.

    PubMed  CAS  Google Scholar 

  54. Welage LS, Schultz RW, Schentag JJ. Pharma­cokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother. 1984; 25:201–4.

    PubMed  CAS  Google Scholar 

  55. Nikolaidis P, Tourkantonis A. Effect of hemodialysis on ceftazidime pharmacokinetics. Clin Nephrol. 1985;24:142–6.

    PubMed  CAS  Google Scholar 

  56. Kinowski JM, de la Coussaye JE, Bressolle F, Fabre D, Saissi G, Bouvet O, Galtier M, Eledjam JJ. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Antimicrob Agents Chemother. 1993;37:464–73.

    PubMed  CAS  Google Scholar 

  57. Losno GR, Santivanez V, Battilana CA. Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis. Chemotherapy. 1988;34:261–6.

    Article  Google Scholar 

  58. Weiss LG, Cars O, Danielson BG, Grahnen A, Wikstrom B. Pharmacokinetics of intravenous ­cefuroxime during intermittent and continuous arteriovenous hemofiltration. Clin Nephrol. 1988;30: 282–6.

    PubMed  CAS  Google Scholar 

  59. Konishi K, Suzuki H, Hayashi M, Saruta T. Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function. J Antimicrob Chemother. 1993;31:413–20.

    Article  PubMed  CAS  Google Scholar 

  60. Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP. Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis. Eur J Clin Pharmacol. 1987;31:589–93.

    Article  PubMed  CAS  Google Scholar 

  61. Roberts AP, Eastwood JB, Gower PE, Fenton CM, Curtis JR. Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects. Eur J Clin Pharmacol. 1978;14:435–9.

    Article  PubMed  CAS  Google Scholar 

  62. Nissenson AR, Wilson C, Holazo A. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis. Am J Nephrol. 1987;7:270–4.

    Article  PubMed  CAS  Google Scholar 

  63. Paap CM, Nahata MC. Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction. DICP. 1989;23:646–54.

    PubMed  CAS  Google Scholar 

  64. Disse B, Gundert-Remy U, Weber E, Andrassy K, Sietzen W, Lang A. Pharmacokinetics of erythromycin in patients with different degrees of renal impairment. Int J Clin Pharmacol Ther Toxicol. 1986;24:460–4.

    PubMed  CAS  Google Scholar 

  65. Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet. 1996;31:1–8.

    Article  PubMed  CAS  Google Scholar 

  66. Dudley MN. Clinical pharmacology of fluconazole. Pharmacotherapy. 1990;10:141S–5.

    PubMed  CAS  Google Scholar 

  67. Nicolau DP, Crowe H, Nightingale CH, Quintiliani R. Effect of continuous arteriovenous hemodiafiltration on the pharmacokinetics of fluconazole. Pharmacotherapy. 1994;14:502–5.

    PubMed  CAS  Google Scholar 

  68. Aweeka FT, Jacobson MA, Martin-Munley S, Hedman A, Schoenfeld P, Omachi R, Tsunoda S, Gambertoglio JG. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:350–7.

    Article  PubMed  CAS  Google Scholar 

  69. Combarnous F, Fouque D, Bernard N, Boulieu R, Chossegros P, Laville M, Zech P. Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. Eur J Clin Pharmacol. 1994;46:379–81.

    Article  PubMed  CAS  Google Scholar 

  70. Boulieu R, Bastien O, Bleyzac N. Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. Ther Drug Monit. 1993;15:105–7.

    Article  PubMed  CAS  Google Scholar 

  71. Ernest D, Cutler DJ. Gentamicin clearance during continuous arteriovenous hemodiafiltration. Crit Care Med. 1992;20:586–9.

    Article  PubMed  CAS  Google Scholar 

  72. Hamann SR, Oeltgen PR, Shank Jr WA, Blouin RA, Natarajan L. Evaluation of gentamicin pharmacokinetics during peritoneal dialysis. Ther Drug Monit. 1982;4:297–300.

    Article  PubMed  CAS  Google Scholar 

  73. Somani P, Freimer EH, Gross ML, Higgins Jr JT. Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 1988;32:530–4.

    PubMed  CAS  Google Scholar 

  74. Verpooten GA, Verbist L, Buntinx AP, Entwistle LA, Jones KH, De Broe ME. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Br J Clin Pharmacol. 1984;18:183–93.

    PubMed  CAS  Google Scholar 

  75. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med. 1999;159:1580–4.

    PubMed  CAS  Google Scholar 

  76. Ellard GA. Chemotherapy of tuberculosis for patients with renal impairment. Nephron. 1993;64: 169–81.

    Article  PubMed  CAS  Google Scholar 

  77. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet. 1988;14:13–34.

    Article  PubMed  CAS  Google Scholar 

  78. Tegeder I, Neumann F, Bremer F, Brune K, Lotsch J, Geisslinger G. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther. 1999;65:50–7.

    Article  PubMed  CAS  Google Scholar 

  79. Giles LJ, Jennings AC, Thomson AH, Creed G, Beale RJ, McLuckie A. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med. 2000;28:632–7.

    Article  PubMed  CAS  Google Scholar 

  80. Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother. 1993;37:229–33.

    PubMed  CAS  Google Scholar 

  81. Somogyi AA, Kong CB, Gurr FW, Sabto J, Spicer WJ, McLean AJ. Metronidazole pharmacokinetics in patients with acute renal failure. J Antimicrob Chemother. 1984;13:183–9.

    Article  PubMed  CAS  Google Scholar 

  82. Ruedy J. The effects of peritoneal dialysis on the physiological disposition of oxacillin, ampicillin and tetracycline in patients with renal disease. Can Med Assoc J. 1966;94:257–61.

    PubMed  CAS  Google Scholar 

  83. Conte Jr JE. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis. 1991;163: 169–75.

    Article  PubMed  Google Scholar 

  84. Conte Jr JE, Upton RA, Lin ET. Pentamidine pharmacokinetics in patients with AIDS with impaired renal function. J Infect Dis. 1987;156:885–90.

    Article  PubMed  Google Scholar 

  85. Thompson MI, Russo ME, Matsen JM, Atkin-Thor E. Piperacillin pharmacokinetics in subjects with chronic renal failure. Antimicrob Agents Chemother. 1981;19:450–3.

    PubMed  CAS  Google Scholar 

  86. Francke EL, Appel GB, Neu HC. Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. Antimicrob Agents Chemother. 1979;16:788–91.

    PubMed  CAS  Google Scholar 

  87. Debruyne D, Ryckelynck JP, Hurault DL, Moulin M. Pharmacokinetics of piperacillin in patients on peritoneal dialysis with and without peritonitis. J Pharm Sci. 1990;79:99–102.

    Article  PubMed  CAS  Google Scholar 

  88. Parry MF, Neu HC. Pharmacokinetics of ticarcillin in patients with abnormal renal function. J Infect Dis. 1976;133:46–9.

    Article  PubMed  CAS  Google Scholar 

  89. Wise R, Reeves DS, Parker AS. Administration of ticarcillin, a new antipseudomonal antibiotic, in patients undergoing dialysis. Antimicrob Agents Chemother. 1974;5:119–20.

    PubMed  CAS  Google Scholar 

  90. Lockwood WR, Bower JD. Tobramycin and gentamicin concentrations in the serum of normal and anephric patients. Antimicrob Agents Chemother. 1973;3:125–9.

    PubMed  CAS  Google Scholar 

  91. Zarowitz BJ, Anandan JV, Dumler F, Jayashankar J, Levin N. Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. J Clin Pharmacol. 1986;26:686–9.

    PubMed  CAS  Google Scholar 

  92. Izzedine H, Mercadal L, Aymard G, Launay-Vacher V, Martinez V, Issad B, Deray G. Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. Am J Nephrol. 2001;21:162–4.

    Article  PubMed  CAS  Google Scholar 

  93. Smiley ML, Murray A, de Miranda P. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Adv Exp Med Biol. 1996;394:33–9.

    PubMed  CAS  Google Scholar 

  94. Vaudry W, Ettenger R, Jara P, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant. 2009;9:636–43.

    Article  PubMed  CAS  Google Scholar 

  95. Kandrotas RJ, Oles KS, Gal P, Love JM. Carbamazepine clearance in hemodialysis and hemoperfusion. DICP. 1989;23:137–40.

    PubMed  CAS  Google Scholar 

  96. Lee CS, Wang LH, Marbury TC, Bruni J, Perchalski RJ. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. Clin Toxicol. 1980;17:429–38.

    Article  PubMed  CAS  Google Scholar 

  97. Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. Drugs Exp Clin Res. 1993;19:25–32.

    PubMed  CAS  Google Scholar 

  98. Garnett WR. Lamotrigine: pharmacokinetics. J Child Neurol. 1997;12(Supply 1):S10–5.

    Article  PubMed  Google Scholar 

  99. Porto I, John EG, Heilliczer J. Removal of phenobarbital during continuous cycling peritoneal dialysis in a child. Pharmacotherapy. 1997;17:832–5.

    PubMed  CAS  Google Scholar 

  100. Czajka PA, Anderson WH, Christoph RA, Banner Jr W. A pharmacokinetic evaluation of peritoneal dialysis for phenytoin intoxication. J Clin Pharmacol. 1980;20:565–9.

    PubMed  CAS  Google Scholar 

  101. Lapierre O, Dubreucq JL, Beauchemin MA, Vinet B. Valproic acid intoxication in a patient with bipolar disorder and chronic uremia. Can J Psychiatry. 1999;44:188.

    PubMed  CAS  Google Scholar 

  102. Orr JM, Farrell K, Abbott FS, Ferguson S, Godolphin WJ. The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. Eur J Clin Pharmacol. 1983;24:387–90.

    Article  PubMed  CAS  Google Scholar 

  103. Doyle GD, Donohue J, Carmody M, Laher M, Greb H, Volz M. Pharmacokinetics of amlodipine in renal impairment. Eur J Clin Pharmacol. 1989;36:205–8.

    Article  PubMed  CAS  Google Scholar 

  104. Laher MS, Kelly JG, Doyle GD, Carmody M, Donohoe JF, Greb H, Volz M. Pharmacokinetics of amlodipine in renal impairment. J Cardiovasc Pharmacol. 1988;12(Supply 7):S60–3.

    Article  PubMed  Google Scholar 

  105. Wan SH, Koda RT, Maronde RF. Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol. 1979;7:569–74.

    PubMed  CAS  Google Scholar 

  106. Salahudeen AK, Wilkinson R, McAinsh J, Bateman DN. Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. Br J Clin Pharmacol. 1984;18:457–60.

    PubMed  CAS  Google Scholar 

  107. Flouvat B, Decourt S, Aubert P, Potaux L, Domart M, Goupil A, Baglin A. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. Br J Clin Pharmacol. 1980;9: 379–85.

    PubMed  CAS  Google Scholar 

  108. Ferguson RK, Rotmensch HH, Vlasses PH. Clinical use of captopril. Illustrative cases. JAMA. 1982;247: 2117–9.

    Article  PubMed  CAS  Google Scholar 

  109. Sica DA, Gehr TW, Fernandez A. Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease. Drug Saf. 2000;22:350–60.

    Article  PubMed  CAS  Google Scholar 

  110. Fujimura A, Kajiyama H, Ebihara A, Iwashita K, Nomura Y, Kawahara Y. Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. Nephron. 1986;44:324–8.

    Article  PubMed  CAS  Google Scholar 

  111. Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ. Elimination kinetics of captopril in patients with renal failure. Kidney Int. 1984;25:942–7.

    Article  PubMed  CAS  Google Scholar 

  112. Lowenthal DT, Saris SD, Paran E, Cristal N. The use of transdermal clonidine in the hypertensive patient with chronic renal failure. Clin Nephrol. 1993; 39:37–43.

    PubMed  CAS  Google Scholar 

  113. Rosansky SJ, Johnson KL, McConnell J. Use of transdermal clonidine in chronic hemodialysis patients. Clin Nephrol. 1993;39:32–6.

    PubMed  CAS  Google Scholar 

  114. Doherty JE, Flanigan WJ, Perkins WH, Ackerman GL. Studies with tritiated digoxin in anephric human subjects. Circulation. 1967;35:298–303.

    PubMed  CAS  Google Scholar 

  115. Iisalo E, Forsstrom J. Elimination of digoxin during maintenance haemodialysis. Ann Clin Res. 1974;6: 203–6.

    PubMed  CAS  Google Scholar 

  116. Pancorbo S, Comty C. Digoxin pharmacokinetics in continuous peritoneal dialysis. Ann Intern Med. 1980;93:639.

    PubMed  CAS  Google Scholar 

  117. Golper TA, Bennett WM. Drug removal by continuous arteriovenous haemofiltration. A review of the evidence in poisoned patients. Med Toxicol Adverse Drug Exp. 1988;3:341–9.

    PubMed  CAS  Google Scholar 

  118. Sica DA, Cutler RE, Parmer RJ, Ford NF. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet. 1991;20:420–7.

    Article  PubMed  CAS  Google Scholar 

  119. Mason NA. Angiotensin-converting enzyme inhibitors and renal function. DICP. 1990;24:496–505.

    PubMed  CAS  Google Scholar 

  120. Lowenthal DT, Porter RS, Saris SD, Bies CM, Slegowski MB, Staudacher A. Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol. 1985;56:14F–8.

    Article  PubMed  CAS  Google Scholar 

  121. Flaherty JF, Wong B, La Follette G, Warnock DG, Hulse JD, Gambertoglio JG. Pharmacokinetics of esmolol and ASL-8123 in renal failure. Clin Pharmacol Ther. 1989;45:321–7.

    Article  PubMed  CAS  Google Scholar 

  122. Gehr TWB, Sica DA, Grasela DM, et al. The pharmacokinetcs and pharmacodynamics of fosinopril in haemodialysis patients. Eur J Clin Pharmacol. 1993;45:431–6.

    Article  PubMed  CAS  Google Scholar 

  123. Gehr TW, Sica DA, Grasela DM, et al. Fosinopril pharmacokineitcs and pharmacodynamics in chronic peritoneal dialysis patients. Eur J Clin Pharmacol. 1991;41:165–9.

    Article  PubMed  CAS  Google Scholar 

  124. Wood AJ, Ferry DG, Bailey RR. Elimination kinetics of labetalol in severe renal failure. Br J Clin Pharmacol. 1982;13:81S–6.

    PubMed  CAS  Google Scholar 

  125. Halstenson CE, Opsahl JA, Pence TV, Luke DR, Sirgo MA, Plachetka JR, Abraham PA, Matzke GR. The disposition and dynamics of labetalol in patients on dialysis. Clin Pharmacol Ther. 1986;40:462–8.

    Article  PubMed  CAS  Google Scholar 

  126. Halstenson CE, Opsahl JA, Wright CE, Fleishaker JC, Andreadis NA, Sobieraj J, Matzke GR. Disposition of minoxidil in patients with various degrees of renal function. J Clin Pharmacol. 1989; 29:798–802.

    PubMed  CAS  Google Scholar 

  127. Spital A, Scandling JD. Nifedipine in continuous ambulatory peritoneal dialysis. Arch Intern Med. 1983;143:2025.

    Article  PubMed  CAS  Google Scholar 

  128. Kleinbloesem CH, van Brummelen P, Woittiez AJ, Faber H, Breimer DD. Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion. Clin Pharmacokinet. 1986;11:316–22.

    Article  PubMed  CAS  Google Scholar 

  129. Herrera J, Vukovich RA, Griffith DL. Elimination of nadolol by patients with renal impairment. Br J Clin Pharmacol. 1979;7(Supply 2):227S–31.

    PubMed  Google Scholar 

  130. Swan SK, Bennett WM. Drug dosing guidelines in patients with renal failure. West J Med. 1992; 156:633–8.

    PubMed  CAS  Google Scholar 

  131. Wood AJ, Vestal RE, Spannuth CL, Stone WJ, Wilkinson GR, Shand DG. Propranolol disposition in renal failure. Br J Clin Pharmacol. 1980;10: 561–6.

    PubMed  CAS  Google Scholar 

  132. Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Cirksena WJ. Pharmacokinetics of oral propranolol in chronic renal disease. Clin Pharmacol Ther. 1974;16:761–9.

    PubMed  CAS  Google Scholar 

  133. Bianchetti G, Graziani G, Brancaccio D, Morganti A, Leonetti G, Manfrin M, Sega R, Gomeni R, Ponticelli C, Morselli PL. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet. 1976;1:373–84.

    Article  PubMed  CAS  Google Scholar 

  134. Follath F, Wenk M, Vozeh S, Thiel G, Brunner F, Loertscher R, Lemaire M, Nussbaumer K, Niederberger W, Wood A. Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther. 1983;34:638–43.

    Article  PubMed  CAS  Google Scholar 

  135. Venkataramanan R, Ptachcinski RJ, Burckart GJ, Yang SL, Starzl TE, Van Theil DH. The clearance of cyclosporine by hemodialysis. J Clin Pharmacol. 1984;24:528–31.

    PubMed  CAS  Google Scholar 

  136. Filler G, Grygas R, Mai I, Stolpe HJ, Greiner C, Bauer S, Ehrich JH. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant. 1997;12: 1668–71.

    Article  PubMed  CAS  Google Scholar 

  137. MacPhee IA, Spreafico S, Bewick M, Davis C, Eastwood JB, Johnston A, Lee T, Holt DW. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int. 2000;57:1164–8.

    Article  PubMed  CAS  Google Scholar 

  138. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429–55.

    Article  PubMed  CAS  Google Scholar 

  139. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990;19:126–46.

    Article  PubMed  CAS  Google Scholar 

  140. Venkataramanan R, Jain A, Warty VS, Abu-Elmagd K, Alessiani M, Lever J, Krajak A, Flowers J, Mehta S, Zuckerman S. Pharmacokinetics of FK 506 in transplant patients. Transplant Proc. 1991;23: 2736–40.

    PubMed  CAS  Google Scholar 

  141. Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med. 1986;80: 41–51.

    Article  PubMed  CAS  Google Scholar 

  142. Awni WM, Yeh J, Halstenson CE, Opsahl JA, Chung M, Matzke GR. Effect of haemodialysis on the pharmacokinetics of cetirizine. Eur J Clin Pharmacol. 1990;38:67–9.

    Article  PubMed  CAS  Google Scholar 

  143. Matzke GR, Chan GL, Abraham PA. Codeine dosage in renal failure. Clin Pharm. 1986;5:15–6.

    PubMed  CAS  Google Scholar 

  144. Buckley MM, Sorkin EM. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs. 1992;44:465–97.

    Article  PubMed  CAS  Google Scholar 

  145. Lin JH, Chremos AN, Yeh KC, Antonello J, Hessey GA. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. Eur J Clin Pharmacol. 1988;34:41–6.

    Article  PubMed  CAS  Google Scholar 

  146. Saima S, Echizen H, Yoshimoto K, Ishizaki T. Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients. J Clin Pharmacol. 1990;30:159–62.

    PubMed  CAS  Google Scholar 

  147. Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H. Pharmacokinetics and dynamics of famotidine in patients with renal failure. Br J Clin Pharmacol. 1988;26:315–21.

    PubMed  CAS  Google Scholar 

  148. Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther. 1984;36:138–44.

    Article  PubMed  CAS  Google Scholar 

  149. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry. 1985;46:14–9.

    PubMed  CAS  Google Scholar 

  150. Bailey RR, Sharman JR, O’Rourke J, Buttimore AL. Haemodialysis and forced diuresis for tricyclic antidepressant poisoning. Br Med J. 1974;4:230–1.

    Article  PubMed  CAS  Google Scholar 

  151. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet. 1996;31:9–28.

    Article  PubMed  CAS  Google Scholar 

  152. Barradell LB, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs. 1992;44:225–50.

    Article  PubMed  CAS  Google Scholar 

  153. Clericetti N, Beretta-Piccoli C. Lithium clearance in patients with chronic renal diseases. Clin Nephrol. 1991;36:281–9.

    PubMed  CAS  Google Scholar 

  154. Matzke GR, Halstenson CE, Opsahl JA, Hilbert J, Perentesis G, Radwanski E, Zampaglione N. Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol. 1990;30:364–71.

    PubMed  CAS  Google Scholar 

  155. Portenoy RK, Foley KM, Stulman J, Khan E, Adelhardt J, Layman M, Cerbone DF, Inturrisi CE. Plasma morphine and morphine-6-glucuronide ­during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain. 1991;47: 13–9.

    Article  PubMed  CAS  Google Scholar 

  156. Naesdal J, Andersson T, Bodemar G, Larsson R, Regardh CG, Skanberg I, Walan A. Pharma­cokinetics of [14 C]omeprazole in patients with impaired renal function. Clin Pharmacol Ther. 1986;40:344–51.

    Article  PubMed  CAS  Google Scholar 

  157. Howden CW, Payton CD, Meredith PA, Hughes DM, Macdougall AI, Reid JL, Forrest JA. Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure. Eur J Clin Pharmacol. 1985;28:637–40.

    Article  PubMed  CAS  Google Scholar 

  158. Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD. The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand Suppl. 1989;350:89–90.

    Article  PubMed  CAS  Google Scholar 

  159. McFadyen ML, Folb PI, Miller R, Keeton GR, Marks IN. Pharmacokinetics of ranitidine in patients with chronic renal failure. Eur J Clin Pharmacol. 1983;25:347–51.

    Article  PubMed  CAS  Google Scholar 

  160. Zech PY, Chau NP, Pozet N, Labeeuw M, Hadj-Aissa A. Ranitidine kinetics in chronic renal impairment. Clin Pharmacol Ther. 1983;34:667–72.

    Article  PubMed  CAS  Google Scholar 

  161. Gladziwa U, Krishna DR, Klotz U, Ittel TH, Schunkert H, Glockner WM, Mann H. Pharma­cokinetics of ranitidine in patients undergoing ­haemofiltration. Eur J Clin Pharmacol. 1988;35: 427–30.

    Article  PubMed  CAS  Google Scholar 

  162. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6–13.

    Article  PubMed  CAS  Google Scholar 

  163. Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther. 2007;81:510–6.

    Article  PubMed  CAS  Google Scholar 

  164. Bouman CSC. Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous veno-venous hemofiltration. Curr Opin Crit Care. 2008;14:654–9.

    Article  PubMed  Google Scholar 

  165. Blowey DL, Warady BA, Abdel-Rahman S, Frye RF, Manley HJ. Vancomycin disposition following intraperitoneal administration in children receiving peritoneal dialysis. Perit Dial Int. 2007;27: 79–85.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Children’s Mercy Hospital and University of Missouri, Kansas City, MO, USA

    Douglas L. Blowey MD

  2. Department of Pediatrics, Division of Pharmacology and Medical Toxicology, Children’s Mercy Hospitals and Clinics, Kansas City, MO, USA

    J. Steven Leeder PharmD, PhD

Authors
  1. Douglas L. Blowey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Steven Leeder PharmD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas L. Blowey MD .

Editor information

Editors and Affiliations

  1. Children’s Mercy Hospital and Clinics, Department of Pediatrics, Section of Pediatric Nephrology, School of Medicine, Kansas City, 64108, Missouri, USA

    Bradley A. Warady

  2. Center for Pediatrics, and Adolescent Medicine, Division of Pediatric Nephrology, Im Neuenheimer Feld 150, Heidelberg, 69120, Germany

    Franz Schaefer

  3. Department of Pediatrics, Stanford University School of Medicine, Division of Pediatric Nephrology, Welch Road 770, Palo Alto, 94304, California, USA

    Steven R. Alexander

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Blowey, D.L., Leeder, J.S. (2012). Drug Administration and Pharmacogenomics in Children Receiving Acute or Chronic Renal Replacement Therapy. In: Warady, B., Schaefer, F., Alexander, S. (eds) Pediatric Dialysis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0721-8_31

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-0721-8_31

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-0720-1

  • Online ISBN: 978-1-4614-0721-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation